William M. Winston

1.8k total citations · 1 hit paper
24 papers, 1.4k citations indexed

About

William M. Winston is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, William M. Winston has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in William M. Winston's work include CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Cancer Research and Treatments (5 papers). William M. Winston is often cited by papers focused on CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Cancer Research and Treatments (5 papers). William M. Winston collaborates with scholars based in United States, Canada and Japan. William M. Winston's co-authors include Craig P. Hunter, Christina Molodowitch, Marie E. Sutherlin, Amanda J. Wright, Evan H. Feinberg, Solly Weiler, Jenő Gyuris, Zhigang Weng, Lorena Lerner and Kristan Meetze and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

William M. Winston

23 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systemic RNAi in C. elegans Requires the Putative Transmembrane Protein SID-1

2002 650 citations William M. Winston, Christina Molodowitch et al. Science profile →

Peers

William M. Winston

AGING

IMMUN

Ruth Böhni Switzerland

Laura A. L. Dillon United States

Philippe Valenti France

Klaus Förstemann Germany

Jumin Zhou United States

Richard Roy Canada

Timm Weber Germany

Jonathan Houseley United Kingdom

Mikel Zaratiegui United States

Taku Naito Japan

Ruth Böhni Switzerland

William M. Winston

889 ×0.9

229 ×0.9

AGING

104 ×0.5

415 ×2.6

IMMUN

98 ×0.6

Citations per year, relative to William M. Winston William M. Winston (= 1×) peers Ruth Böhni

Countries citing papers authored by William M. Winston

Since Specialization

Citations

This map shows the geographic impact of William M. Winston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William M. Winston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William M. Winston more than expected).

Fields of papers citing papers by William M. Winston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William M. Winston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William M. Winston. The network helps show where William M. Winston may publish in the future.

Co-authorship network of co-authors of William M. Winston

This figure shows the co-authorship network connecting the top 25 collaborators of William M. Winston. A scholar is included among the top collaborators of William M. Winston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William M. Winston. William M. Winston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morris, Kristin, Daniel J. Hicklin, Christopher J. Nirschl, et al.. (2024). Abstract 4074: Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models. Cancer Research. 84(6_Supplement). 4074–4074. 2 indexed citations

Nirschl, Christopher J., Connor J. Dwyer, Daniel J. Hicklin, et al.. (2023). mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity. Cancer Immunology Research. 11(7). 962–977. 8 indexed citations

Shirasuna, Kenna, Gerald Koelsch, Cynthia Seidel‐Dugan, et al.. (2021). Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody. Cancer Treatment and Research Communications. 28. 100433–100433. 10 indexed citations

Tyagi, Ethika, Dan Hicklin, Nesreen S. Ismail, et al.. (2021). 723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models. SHILAP Revista de lepidopterología. A752–A752. 3 indexed citations

Steiner, Philipp, Dan Hicklin, Nesreen S. Ismail, et al.. (2021). Abstract 1716: WTX-330, a conditionally activated IL-12 INDUKINE, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models. Cancer Research. 81(13_Supplement). 1716–1716. 4 indexed citations

Steiner, Philipp, Daniel J. Hicklin, Randi Isaacs, et al.. (2021). Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates. Blood. 138(Supplement 1). 2258–2258. 9 indexed citations

Morris, Kristin, Daniel J. Hicklin, Nesreen S. Ismail, et al.. (2021). 715 WTX-330 is an IL-12 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models. SHILAP Revista de lepidopterología. A744–A744. 2 indexed citations

Salmerón, Andrés, Daniel J. Hicklin, Nesreen S. Ismail, et al.. (2021). Abstract 1723: WTX-124 is an IL-2 pro-drug conditionally activated in tumors and able to induce complete regressions in mouse tumor models. Cancer Research. 81(13_Supplement). 1723–1723. 1 indexed citations

Proia, Theresa A., Feng Jiang, Richard Nicoletti, et al.. (2015). 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity. Molecular Cancer Therapeutics. 14(8). 1858–1867. 8 indexed citations

10.

Lerner, Lorena, Nianjun Tao, Brian Krieger, et al.. (2015). Abstract 1153: Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody. Cancer Research. 75(15_Supplement). 1153–1153. 4 indexed citations

11.

Meetze, Kristan, Sylvie Vincent, Steve Bottega, et al.. (2014). Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models. Clinical Cancer Research. 21(5). 1106–1114. 41 indexed citations

12.

Vincent, Sylvie, Christina Fleet, Donna McIntosh, et al.. (2012). Abstract 2509: AV-203, a humanized ERBB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ERBB3 signaling in vitro and in vivo. Cancer Research. 72(8_Supplement). 2509–2509. 7 indexed citations

13.

Gifford, James, Kristan Meetze, William M. Winston, et al.. (2011). Abstract 644: Anti-tumor activities of antibodies targeting the RON receptor and a biomarker of response. Cancer Research. 71(8_Supplement). 644–644. 1 indexed citations

14.

Bai, Ailin, Kristan Meetze, William M. Winston, et al.. (2010). GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling. Cancer Research. 70(19). 7630–7639. 123 indexed citations

15.

Han, Mi Seon, K. Whalen, Kristan Meetze, et al.. (2010). 2LB Anti-tumor activity of anti-RON antibodies and biomarker of response. European Journal of Cancer Supplements. 8(7). 3–3. 1 indexed citations

16.

Okamura, Heidi, William M. Rideout, William M. Winston, et al.. (2010). Abstract 5170: Monoclonal antibodies to Notch receptors inhibit tumor maintenance. Cancer Research. 70(8_Supplement). 5170–5170. 2 indexed citations

17.

Winston, William M., Marie E. Sutherlin, Amanda J. Wright, Evan H. Feinberg, & Craig P. Hunter. (2007). Caenorhabditis elegans SID-2 is required for environmental RNA interference. Proceedings of the National Academy of Sciences. 104(25). 10565–10570. 230 indexed citations

18.

Hunter, Craig P., William M. Winston, Christina Molodowitch, et al.. (2006). Systemic RNAi in Caenorhabditis elegans. Cold Spring Harbor Symposia on Quantitative Biology. 71(0). 95–100. 54 indexed citations

19.

Winston, William M., Christina Molodowitch, & Craig P. Hunter. (2002). Systemic RNAi in C. elegans Requires the Putative Transmembrane Protein SID-1. Science. 295(5564). 2456–2459. 650 indexed citations breakdown →

20.

Berger, Imre, William M. Winston, Ramasamy Manoharan, et al.. (1998). Spectroscopic Characterization of a DNA-Binding Domain, Zα, from the Editing Enzyme, dsRNA Adenosine Deaminase: Evidence for Left-Handed Z-DNA in the Zα−DNA Complex. Biochemistry. 37(38). 13313–13321. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact